PROF Archives - Page 4 of 7

Developments

Profound Medical nearly doubles Q1 revenue

Profound Medical (NASDAQ:PROF; TSX:PRN) posted revenue of $1.4-million in the first quarter, up 92%, from $711,000 in the year earlier quarter. In the latest period, the company generated $1.02-million from recurring...

May 9, 2022

Developments

Profound Medical gets high marks from Cowen on KOL webinar for TULSA-PRO

A key opinion leader highlighted the numerous technology advancements and clinical advantages of Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO treatment of prostate diseases at a company hosted clinical education...

May 2, 2022

Developments

Profound Medical CEO adds to holdings

Profound Medical (NASDAQ:PROF; TSX:PRN) chairman and CEO, Arun Menawat, acquired a total of 60,599 shares of Profound on the open market at a cost of $497,180 (U.S.). According to a filing with SEDI, Dr. Menawat...

March 11, 2022

Developments

Profound Medical treats first patients in Level 1 post-market study comparing TULSA procedure to radical prostatectomy

Profound Medical (NASDAQ:PROF; TSX:PRN) treated the first patients in the Level 1 CAPTAIN trial comparing the TULSA procedure (performed with its TULSA-PRO system) against radical prostatectomy (RP). The prospective...

January 18, 2022

Executive Moves

Global medical device executive Kenneth Knudson joins Profound as CCO

Profound Medical (NASDAQ:PROF; TSX:PRN) appointed accomplished global medical device industry veteran, Kenneth Knudson, as chief commercial officer to lead Profound’s worldwide sales, marketing and reimbursement...

January 5, 2022

Developments

Profound Medical gets recommendation from Timelo Investment

During a BNN Bloomberg TV interview, Jean-Francois Tardif, founder and portfolio manager of Timelo Investment Management, praised the prospects of Profound Medical (NASDAQ:PROF; TSX:PRN). “Profound has an FDA-approved...

September 20, 2021

Developments

Raymond James study finds superior safety and TAM with Profound Medical’s TULSA-PRO

Raymond James gave winning marks to Profound Medical‘s (NASDAQ:PROF; TSX:PRN) TULSA-PRO device, compared with the Focal One HIFU device from France’s EDAP TMS SA (NASDAQ:EDAP), in a head-to-head comparison study...

August 26, 2021

Developments

Profound Medical posts sequential 145% jump in Q2 recurring revenue

Profound Medical (NASDAQ:PROF; TSX:PRN) reported a 145% increase in recurring revenue for the second quarter, compared with the first quarter of 2021. Total revenue, including capital sales outside of the U.S...

August 5, 2021

Developments

Profound’s TULSA-PRO posts better safety, equal efficacy in real-world analysis of prostate cancer partial ablation, BPH

A peer-reviewed paper authored by clinicians and researchers from Germany’s ALTA Klinik and the University Hospital, LMU Munich, and published in Urologic Oncology illustrates that Profound Medical’s...

June 21, 2021

Developments

Profound Medical, Akumin in U.S. multi-center commercial pact for TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) signed a multi-site imaging center agreement for its TULSA-PRO device with Akumin (NASDAQ, TSX:AKU), a leading provider of freestanding, fixed-site outpatient diagnostic imaging...

May 6, 2021

Tag - PROF

Profound Medical nearly doubles Q1 revenue

Profound Medical gets high marks from Cowen on KOL webinar for TULSA-PRO

Profound Medical CEO adds to holdings

Profound Medical treats first patients in Level 1 post-market study comparing TULSA procedure to radical prostatectomy

Global medical device executive Kenneth Knudson joins Profound as CCO

Profound Medical gets recommendation from Timelo Investment

Raymond James study finds superior safety and TAM with Profound Medical’s TULSA-PRO

Profound Medical posts sequential 145% jump in Q2 recurring revenue

Profound’s TULSA-PRO posts better safety, equal efficacy in real-world analysis of prostate cancer partial ablation, BPH

Profound Medical, Akumin in U.S. multi-center commercial pact for TULSA-PRO

General

More